[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Zenas Biopharma Inc (ZBIO)

Zenas Biopharma Inc (ZBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,157,859
  • Shares Outstanding, K 63,133
  • Annual Sales, $ 10,000 K
  • Annual Income, $ -377,740 K
  • EBIT $ -383 M
  • EBITDA $ -383 M
  • 60-Month Beta -0.61
  • Price/Sales 119.32
  • Price/Cash Flow N/A
  • Price/Book 3.23

Options Overview Details

View History
  • Implied Volatility 90.28% (-12.67%)
  • Historical Volatility 71.97%
  • IV Percentile 9%
  • IV Rank 11.83%
  • IV High 189.19% on 01/02/26
  • IV Low 77.01% on 11/12/25
  • Expected Move (DTE 31) 0.94 (5.10%)
  • Put/Call Vol Ratio 0.28
  • Today's Volume 100
  • Volume Avg (30-Day) 73
  • Put/Call OI Ratio 0.61
  • Today's Open Interest 4,861
  • Open Int (30-Day) 4,731
  • Expected Range 17.41 to 19.28

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.83
  • Number of Estimates 3
  • High Estimate $-0.12
  • Low Estimate $-1.29
  • Prior Year $-1.25
  • Growth Rate Est. (year over year) +33.60%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.39 +5.49%
on 05/15/26
22.15 -17.20%
on 05/05/26
-2.71 (-12.87%)
since 04/15/26
3-Month
17.20 +6.63%
on 03/27/26
29.55 -37.94%
on 02/17/26
-8.06 (-30.53%)
since 02/13/26
52-Week
8.91 +105.84%
on 07/02/25
44.60 -58.88%
on 12/24/25
+8.60 (+88.30%)
since 05/15/25

Most Recent Stories

More News
Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor

- Phase 1 trial designed to evaluate the safety, tolerability, and pharmacokinetic properties of ZB021 in healthy volunteers and to establish proof-of-concept in patients with plaque psoriasis - -...

ZBIO : 18.34 (-2.96%)
Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

– Obexelimab marketing applications for the treatment of IgG4-RD on-target for submission to the FDA this quarter and the EMA in H2 2026 based on the Phase 3 INDIGO IgG4-RD trial results – –...

ZBIO : 18.34 (-2.96%)
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader...

ZBIO : 18.34 (-2.96%)
Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million

WALTHAM, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed...

ZBIO : 18.34 (-2.96%)
Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock

WALTHAM, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed...

ZBIO : 18.34 (-2.96%)
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader...

ZBIO : 18.34 (-2.96%)
Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

- Obexelimab marketing applications for the treatment of IgG4-RD expected to be submitted to the FDA in Q2 2026 and the EMA in H2 2026 based on the Phase 3 INDIGO trial results - - Topline results...

ZBIO : 18.34 (-2.96%)
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader...

ZBIO : 18.34 (-2.96%)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Zenas BioPharma, Inc. (NASDAQ: ZBIO)

NEW YORK , Feb. 17, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Zenas BioPharma, Inc. (NASDAQ: ZBIO) on behalf of the company's shareholders. The investigation...

ZBIO : 18.34 (-2.96%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO

NEW YORK , Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO). Such investors are advised...

ZBIO : 18.34 (-2.96%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Zenas BioPharma Inc. is a clinical-stage global biopharmaceutical company. It involved in the development and commercialization of transformative immunology-based therapies for patients in need. The company's lead product candidate includes obexelimab and Fc'RIIb. Zenas BioPharma Inc. is based in WALTHAM,...

See More

Key Turning Points

3rd Resistance Point 19.98
2nd Resistance Point 19.27
1st Resistance Point 18.81
Last Price 18.34
1st Support Level 17.63
2nd Support Level 16.92
3rd Support Level 16.46

See More

52-Week High 44.60
Fibonacci 61.8% 30.97
Fibonacci 50% 26.75
Fibonacci 38.2% 22.54
Last Price 18.34
52-Week Low 8.91

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.